1.17
+0.055(+4.96%)
Currency In USD
Address
561 Eccles Avenue
South San Francisco, CA 94080
United States of America
Phone
650 489 9000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
October 31, 2019
| Name | Title | Pay | Year Born |
| Dr. Brian Russell Wong M.D., Ph.D. | Chief Executive Officer, President & Director | 861,242 | 1972 |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer | 490,250 | 1969 |
| Mr. Rodney K. B. Young | Chief Financial Officer, Principal Accounting Officer & Secretary | 616,564 | 1963 |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer | 620,322 | 1965 |
| Mr. Michael Listgarten | General Counsel | 0 | N/A |
| Dr. Nipun Davar MBA, Ph.D. | Senior Vice President of Technical Operations | 0 | 1968 |
| Dr. Paul Kassner Ph.D. | Senior Vice President of Biology | 0 | 1967 |
| Steve Young Ph.D. | Vice President of Technology | 0 | N/A |
| Ms. Jennifer Nicholson | Senior Vice President of Regulatory Affairs & Quality Assurance | 0 | N/A |
| Ms. Gwen R. Carscadden | Chief Human Resources Officer | 0 | 1961 |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.